Valuation: Milestone Pharmaceuticals Inc.

Market Cap 177M 155M 143M 131M 248M 17.02B 253M 1.7B 668M 8.32B 664M 650M 28.67B P/E 2026 *
-1.4x
P/E 2027 * -1.27x
Enterprise Value 177M 155M 143M 131M 248M 17.02B 253M 1.7B 668M 8.32B 664M 650M 28.67B EV / Sales 2026 *
24.8x
EV / Sales 2027 * 5.99x
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Milestone Pharmaceuticals Inc.

1 day-2.69%
1 week+4.10%
Current month-5.22%
1 month-3.05%
3 months-42.27%
6 months-37.44%
Current year-37.13%
1 week 1.22
Extreme 1.22
1.32
1 month 1.2
Extreme 1.2
1.42
Current year 1
Extreme 1
2.34
1 year 1
Extreme 1
3.06
3 years 0.63
Extreme 0.6254
3.62
5 years 0.63
Extreme 0.6254
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 2017-03-06
Director of Finance/CFO 53 2019-09-08
Compliance Officer 48 2026-02-09
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 60 2019-03-31
Director/Board Member 67 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

77,000 0.0618%
06-09Free

Director

77,000 0.0618%
06-09Free

Chairman

77,000 0.0618%
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%+4.10%-14.19%-62.97% 177M
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.40%-5.88%+6.62%+429.86% 23.87B
+1.74%-2.17%-17.31%-14.65% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.38%-0.96%+26.12%+189.58% 14.02B
Average +2.31%+0.38%+47.83%+175.88% 23.94B
Weighted average by Cap. +2.08%+0.47%+52.96%+157.50%

Financials

2026 *2027 *
Net sales 7.14M 6.25M 5.76M 5.3M 10.04M 687M 10.21M 68.79M 26.99M 336M 26.83M 26.24M 1.16B 29.53M 25.82M 23.81M 21.89M 41.48M 2.84B 42.19M 284M 112M 1.39B 111M 108M 4.79B
Net income -112M -98.3M -90.68M -83.35M -158M -10.82B -161M -1.08B -425M -5.29B -422M -413M -18.22B -129M -112M -104M -95.38M -181M -12.38B -184M -1.24B -486M -6.05B -483M -473M -20.86B
Net Debt - -
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change Volume
26-07-15 US$1.266 -2.62% 665,037
26-07-14 US$1.300 +1.56% 868,386
26-07-13 US$1.280 0.00% 511,197
26-07-10 US$1.280 -2.29% 457,238
26-07-09 US$1.310 +7.38% 809,241
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.300USD
Average target price
6.333USD
Spread / Average Target
+387.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIST Stock